Innate Immune Response During Community Acquired Pneumonia

Acute Respiratory Distress Syndrome Clinical Trial

— ImPACT  

Official title:

Innate Immunity During Community Acquired Pneumonia: A Translational Approach

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03379207
• Other study ID #: PHAO17/YJ-ImPACT
• Status: Recruiting
• Start date: January 10, 2018
• Est. completion date: March 19, 2025

Study information

• Verified date: December 2023
• Source: University Hospital, Tours
• Contact: Youenn JOUAN, MD-PHD
• Phone: +33 247479861
• Email: youenn.jouan[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Community acquired pneumonia (CAP) is a major cause of morbidity and mortality worldwide. Despite recent improvement in acute management (specifically for administration of antibiotics) many severe presentations of pneumonia worsen, progressing to Acute Respiratory Distress Syndrome (ARDS), a clinical entity with 40% hospital mortality.

Dysregulation of immune response is thought to be largely implicated in severe pneumonia progressing to ARDS. Notably, experimental studies have recently suggested the implication of non-conventional T lymphocytes and innate cells in this immunopathology. However, no data are available in Humans in clinical settings.

This study aims to explore the role of non-conventional T cells in pneumonia and ARDS, in participants. For this purpose, 100 participants admitted to Intensive Care Unit (ICU) with a diagnosis of CAP will be included, and 50 "control" participants with no pneumonia nor shock. Presence and functionality of non-conventional T cells and innate cells will be explored using flow-cytometry and ex-vivo stimulation, alongside with cytokines productions. These analyses are conducted in the blood, and, for invasively ventilated participants, in tracheal aspirates or broncho-alveolar fluids if available. For each participants included, the analyses are conducted at different time-points during ICU stay: inclusion, day 3, day 8 and day 15. Moreover, participants with ARDS, for whom a post-ICU follow-up program is normally established after discharge, will have blood analysis from blood samples taken during the follow-up visit up to 8 months after inclusion.

Immunophenotypage and functionality of non-conventional T cells and innate cells will be compared to clinical parameters and their evolution, between "CAP" participants and "Control" participants", and for each participants, according to the different time-point of analysis, in order to better understand dynamic of innate immunity during pneumonia and ARDS.

Description:

• Clinical and scientific background:

Community acquired pneumonia is a major cause of morbidity and mortality worldwide. Despite recent improvement in acute management (specifically for administration of antibiotics), severe pneumonia can worsen and ultimately progressing to Acute Respiratory Distress Syndrome (ARDS), a clinical entity with an inacceptable 40% hospital mortality. From a pathophysiological point of view, ARDS is characterized by a deregulation of pulmonary inflammation initially triggered by the local aggression, which is, in two-third of the cases, a pneumonia. Alteration of tissue repair is another major characteristic of this entity. So far, the scientific knowledge on this pathophysiology did not translate into specific therapy that could modulate efficiently the inflammatory response and to control the progression from pneumonia to ARDS, and/or to improve tissue repair. Thus, a complete reconsideration of the pathophysiological mechanisms is mandatory. Recent progresses in mucosal biology and innate immunity give interesting new opportunities. Specifically, recently discovered unconventional T cells have shown to be major actors in shaping and modulating early immune responses in the lung mucosa during microbial aggressions and for secondary tissue repair. However, these evidences are limited to pre-clinical models. In many other human diseases (oncology, immune diseases), these sub-populations are already being explored as potential targets for immune therapies.

• Objective of the study:

The aim of this study is to explore potential implications of unconventional T cells during human severe pneumonia and ARDS.

This translational study will complement experimental approaches currently undertaken in the laboratory exploring the role of unconventional T cells in murine models of severe pneumonia and ARDS.

• Design:

This is a prospective single-center study including participants admitted in Intensive Care Department of the university hospital of Tours for community-acquired pneumonia. Given the exploratory nature of the study, we designed a "control" group of participants admitted to ICU without evident signs of pneumonia and shock.

Number of participants: 300 for "pneumonia" group, and 50 for "control" group

• Interventions and analysis:

Blood samples will be collected at inclusion, day 3, 8 and 15 during patient's stay in ICU. For mechanically ventilated participants, tracheal aspirates will be also collected at the same timing. If available, broncho-alveolar lavages will be also collected. If ARDS or Ventilator Associated Pneumonia (VAP) are subsequently diagnosed, supplemental blood and tracheal aspirates samples will be collected.

Blood samples and airway fluid samples will be treated to perform flow cytometry analysis for immunophenotypage (cellular content). In some cases, intra-cellular staining will be performed to assess cytokine production and/or transcription factor expression. Functions of unconventional T cells will also be performed after ex vivo stimulation on purified population (cell sorting). Cytokine level sand transcriptomic analyses will also be performed on blood samples.

Clinical characteristics (including respiratory parameters, blood gas, organ dysfunctions, survival at day 28 and day 90) will also be collected. Thus, frequency, activation status and functions of unconventional T cells will be dynamically analyzed in regard of clinical evolution within-individuals and across pneumonia vs control groups. A particular focus will be made on respiratory parameters (ventilation mode, and for participants with ARDS, P/F ratio, driving pressure), organ dysfunctions (as measured by SOFA score), and microbial documentation of the pneumonia.

Moreover, participants treated for ARDS are usually followed in a post-ICU follow-up clinic program in the ICU where the research is conducted. Thus, investigators will perform analysis of the unconventional T cell compartment (blood samples) in the participants firstly enrolled in the study. This will allow exploration of long-term imprinting on the innate immune response after the initial trigger.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 350
• Est. completion date: March 19, 2025
• Est. primary completion date: September 9, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

"Pneumonia" group:

• Admission to the Intensive Care Units or Pneumonia service of Tours University Hospital or Intensive Care Unit or Limoges University Hospital

• Initial diagnosis of acute community-acquired pneumonia suggested by the presence of a cough, dirty sputum, chest pain and / or dyspnea (at least two criteria required), associated with the presence of a radiological or CT infiltrate initially

• Patient for whom it is not envisaged, a priori, to limit treatment within 5 days following inclusion, for ethical reasons, due to age and advanced comorbidities, and / or a level of severity beyond all therapeutic possibilities.

• Diagnosis of pneumonia done within 48 hours after admission to the hospital

• Participant admitted to the hospital for less than 8 days

"Control" group:

• Admission to the Intensive Care Units of the University Hospital of Tours or Limoges University Hospital

• Use of invasive mechanical ventilation for less than 48 hours

• Predictable duration of invasive mechanical ventilation> 48h

• Participant admitted to the hospital for less than 8 days

• Absence of pneumonia criteria (according to the criteria defined for the "Pneumonia" participant group)

• Absence shock (defined by the need for vasopressor despite volume expansion =30mL/kg, associated with a blood lactate level = 2mmol / L

• Patient for whom it is not envisaged, a priori, to limit treatment within 5 days following inclusion, for ethical reasons, due to age and advanced comorbidities, and / or a level of severity beyond all therapeutic possibilities.

Exclusion Criteria:

• Participant under protection

• Pregnant or lactating women

Related Conditions & MeSH terms

• Acute Lung Injury
• Acute Respiratory Distress Syndrome
• Community-acquired Pneumonia
• Innate Immunity
• Pneumonia
• Respiratory Distress Syndrome
• Respiratory Distress Syndrome, Newborn

Intervention

Other:
• Blood samples
Blood samples for research purpose, taken whenever possible during blood sampling for routine purpose
• Tracheal Aspirates
Only for mechanically ventilated participants.
• Surplus of Broncho-alveolar lavage fluid
Only if performed for diagnosis purpose by the treating investigator : indication left at his discretion

Locations

Country	Name	City	State
France	University Hospital of LIMOGES	Limoges
France	University Hospitakl of TOURS Département of Pneumonia	Tours
France	University Hospital -Bretonneau - Intensive Care	Tours
France	University Hospital of Tours; INSERM CIC 1415	Tours

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Tours

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blood level of Non-Conventional T Lymphocytes (expressed as % CD3+ lymphocytes)		8 Months
Primary	Airway level of Non-Conventional T Lymphocytes (expressed as % CD3+ lymphocytes)		8 Months
Primary	Blood level of inflammatory cytokines		8 months
Primary	Airway level of inflammatory cytokines		8 months
Secondary	Blood level of Conventional T Lymphocytes (expressed as % CD3+ lymphocytes)		8 months
Secondary	Airway level of Conventional T Lymphocytes (expressed as % CD3+ lymphocytes)		8 months
Secondary	Metabolic signature of non-conventional T lymphocytes		8 months
Secondary	Transcriptomic signature of non-conventional T lymphocytes		8 Months
Secondary	Blood level of Innate Cells (expressed as % CD45+ lymphocytes)		8 months
Secondary	AIrway level of Innate Cells (expressed as % CD45+ lymphocytes)		8 months